Showing 2371-2380 of 2656 results for "".
- Regeneron CEO: Manufacturing Not Up to Snuff for COVID-19 Vaccines, Therapieshttps://modernod.com/news/regeneron-ceo-manufacturing-not-up-to-snuff-for-covid-19-vaccines-therapies/2477753/Regeneron has been at the forefront of the COVID-19 fight for months with partnered med Kevzara in clinical trials and an antibody cocktail in development. But success in the clinic means nothing if drugmakers can’t produce a therapy or vaccine fast enough—and the company’s helmsman i
- Novavax Granted Up to $384 Million in New CEPI Funding for COVID-19 Vaccine Candidatehttps://modernod.com/news/novavax-granted-up-to-384-million-in-new-cepi-funding-for-covid-19-vaccine-candidate/2477747/Novavax announced that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in March, to advance clinical development of the company’s vaccine candidate NVX-CoV2373 against SARS-CoV-2. In Ap
- The Allergan Foundation Doubles its COVID-19 Response Donations to $4.0 Millionhttps://modernod.com/news/the-allergan-foundation-doubles-its-covid-19-response-donations-to-4-0-million/2477733/Allergan announced that The Allergan Foundation has fast-tracked another $2 million dollars in charitable grants for community organizations responding to the COVID-19 pandemic. The new grants double The Allergan Foundation’s total COVID-19 donations to date, r
- EyeXam and GenieMD Announce Mobile Collaboration in Eye Carehttps://modernod.com/news/eyexam-and-geniemd-announce-mobile-collaboration-in-eye-care/2477719/Mobile app EyeXam and GenieMD, a global provider of telemedicine solutions, announced a joint venture to introduce eyeXamVirtual, a telemedicine mobile solution. Together, GenieMD and EyeXam’s resources will enable consumers easy access to eye care providers physically and virtually,
- SightGlass Vision Announces R&D Webinar Featuring Leading Myopia Expertshttps://modernod.com/news/sightglass-vision-announces-rd-webinar-featuring-leading-myopia-experts/2477704/SightGlass Vision announced it will hold an R&D webinar to discuss the science of and latest research in myopia, as well as provide an overview about the clinical development and commercialization program for the company’s novel glasses designed to slow the progression of myopia in chil
- Quest Diagnostics Launches First Consumer-Ordered COVID-19 Antibody Testhttps://modernod.com/news/quest-diagnostics-launches-first-consumer-ordered-covid-19-antibody-test/2477674/For about $120, anyone can get now get a COVID-19 antibody test from Quest Diagnostics. The lab company announced Tuesday it launched the first consumer-ordered test—yes, that means there’s no doctor referral needed—to allow patients to check whether they have the antibodies that indicate t
- SightGlass Vision Unveils Topline Data From Study of Novel Eyeglasses Designed to Control Myopia in Childrenhttps://modernod.com/news/sightglass-vision-unveils-topline-data-from-study-of-novel-eyeglasses-designed-to-control-myopia-in-children/2477653/SightGlass Vision announced topline data from the company’s pivotal trial evaluating its novel eyeglasses designed to slow the progression of myopia in children. Results from a planned 12-month interim analysis of the CYPRESS clinical study (NCT03623074) demonstrated a reduction in myopia p
- FDA Authorizes First Test for Patient At-Home Sample Collectionhttps://modernod.com/news/fda-authorizes-first-test-for-patient-at-home-sample-collection/2477635/The FDA has authorized the first diagnostic test with a home collection option for COVID-19. LabCorp’s COVID-19 RT-PCR test allows testing of samples self-collected by patients at home using the company’s Pixel COVID-19 home collection kit. “Throughout this pandemic we have been faci
- GlaxoSmithKline Takes $250 Million Stake in Vir as Companies Pair Up to Develop Coronavirus Treatmentshttps://modernod.com/news/glaxosmithkline-takes-250-million-stake-in-vir-as-companies-pair-up-to-develop-coronavirus-treatments/2477536/GlaxoSmithKline and Vir Biotechnology announced that they have agreed to enter into a collaboration to develop anti-viral antibodies for coronaviruses, including SARS-CoV-2. In addition, to gain access to Vir’s monoclonal antibody technology, GlaxoSmithKline said it will also make an equity
- AAO: Malaria Drugs For COVID-19 Will Not Blind Youhttps://modernod.com/news/aao-malaria-drugs-for-covid-19-will-not-blind-you/2477533/The American Academy of Ophthalmology has shared its latest information about protecting vision during the COVID-19 pandemic. Below are six topics getting a lot of attention right now, and AAO’s recommendations: Avoid touching your eyes By now you